10 completed, 9 recruiting, 1 active not recruiting, 1 approved for marketing. 11 Phase 2, 7 Phase 1, 2 Phase 4, 1 Not applicable, 1 Phase 3.
Follow avapritinib: new trials by email Literature Review of avapritinib trials Research Report on avapritinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany Avapritinib - Indolent Systemic Mastocytosis | Recruiting | Blueprint Medicines Corporation | 80 | 2025-12-09 | 2026-10-07 | |
| Avapritinib Maintenance for AML With KIT Mutations Avapritinib - AML, Adult | Phase 2 | Not yet recruiting | Ruijin Hospital | 47 | 2025-02-01 | 2025-01-09 |
| Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT Avapritinib, azacitidine, Venetoclax - AML (Acute Myelogenous Leukemia) | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-01-20 | 2025-01-20 |
| Avapritinib Rollover Study Avapritinib - Mastocytosis, Systemic | Phase 4 | Recruiting | Blueprint Medicines Corporation | 60 | 2024-11-28 | 2026-02-09 |
| MRD-positive AML Clinical Study Ivosidenib, Gilteritinib, Venetoclax - AML, Adult | Not applicable | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 537 | 2024-05-11 | 2026-08-10 |
| Avapritinib With Decitabine in Patients With SM-AHN Avapritinib, Decitabine, Decitabine/Cedazuridine - Systemic Mastocytosis With an Associated Hematologic Neoplasm | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 34 | 2024-03-13 | 2026-04-01 |
| Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation Avapritinib, Azacitidine Injection, Decitabine Injection - AML, Childhood, Relapse/Recurrence | Phase 2 | Recruiting | Children's Hospital of Soochow University | 50 | 2024-03-01 | 2024-08-22 |
| Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML Homoharringtonine, Cytarabine, Etoposide - AML, Childhood, Acute Myeloid Leukemia | Phase 2 | Recruiting | Children's Hospital of Soochow University | 500 | 2024-01-01 | 2024-08-22 |
| Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World Avapritinib, Tyrosine kinase inhibitors other than avapritinib ( imatinib, sunitinib, et al ) - Gastrointestinal Stromal Tumors | Completed | CStone Pharmaceuticals | 61 | 2022-08-29 | 2026-02-11 | |
| A Drug-drug Interaction Study of Avapritinib and Midazolam Avapritinib, midazolam - Gastrointestinal Stromal Tumors, GIST | Phase 1 | Completed | Blueprint Medicines Corporation | 10 | 2022-08-24 | 2024-12-13 |
| Avapritinib in CBF-AML With KIT Mutations Avapritinib - Core Binding Factor Acute Myeloid Leukemia, KIT Mutation-Related Tumors | Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 50 | 2022-06-01 | 2023-05-09 |
| A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling avapritinib - Solid Tumor, Unspecified, Child, Relapsed Solid Neoplasm | Phase 1 / Phase 2 | Completed | Blueprint Medicines Corporation | 29 | 2022-02-24 | 2026-01-13 |
| Study for Patients Previously Treated in Avapritinib Clinical Trials Avapritinib - Gastrointestinal Stromal Tumors | Phase 4 | Completed | Blueprint Medicines Corporation | 2 | 2021-05-21 | 2024-11-26 |
| Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors Avapritinib - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8 | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2021-01-20 | 2026-06-11 |
| A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors. HDM201, Ribociclib, Cabozantinib - Malignant Solid Tumor | Phase 2 | Recruiting | Centre Leon Berard | 455 | 2020-01-28 | 2026-07-08 |
| A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor CS3007 (BLU-285) - Gastrointestinal Stromal Tumors | Phase 1 / Phase 2 | Completed | CStone Pharmaceuticals | 65 | 2019-08-15 | 2023-04-27 |
| (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis Avapritinib, Placebo - Indolent Systemic Mastocytosis | Phase 2 | Active not recruiting | Blueprint Medicines Corporation | 251 | 2019-04-16 | 2026-10-02 |
| (PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis Avapritinib - Advanced Systemic Mastocytosis, Aggressive Systemic Mastocytosis | Phase 2 | Completed | Blueprint Medicines Corporation | 107 | 2018-11-21 | 2026-10-20 |
| (VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST avapritinib, regorafenib - GIST | Phase 3 | Completed | Blueprint Medicines Corporation | 476 | 2018-03-26 | 2022-10-06 |
| Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Multiple drug microinjection, CIVO device - Soft Tissue Sarcoma Adult | Phase 1 | Completed | Presage Biosciences | 23 | 2016-12-15 | 2021-09-24 |
Showing 20 of 24. Sign in to see all of them.
Gastrointestinal Stromal Tumors (7) · Leukemia, Myeloid, Acute (5) · Mastocytosis, Systemic (5) · Recurrence (4) · Glioma (2) · Leukemia, Mast-Cell (2) · Neoplasm Metastasis (2) · Sarcoma (2) · Central Nervous System Neoplasms (1) · Colorectal Neoplasms (1) · Glioblastoma (1) · Lung Neoplasms (1) · Mastocytosis (1) · Melanoma (1) · Neoplasm, Residual (1)
Blueprint Medicines Corporation (12) · CStone Pharmaceuticals (2) · Children's Hospital of Soochow University (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Centre Leon Berard (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · M.D. Anderson Cancer Center (1) · Presage Biosciences (1) · Ruijin Hospital (1) · The First Affiliated Hospital of Soochow University (1)
United States (10) · China (9) · France (7) · United Kingdom (7) · Germany (6) · Italy (6) · Canada (5) · Netherlands (5) · Belgium (4) · Spain (4) · Austria (3) · Norway (3) · Poland (3) · South Korea (3) · Australia (2)
Shaoyan Hu, MD, PhD (2) · Andrew Kuykendall, MD (1) · Erlie Jiang (1) · Gary Deutsch, MD (1) · Huui Wei, doctor (1) · Jordi Rodon Ahnert (1) · Kenneth Gundle, MD (1) · Seth Pollack, MD (1) · Suning Chen (1)
PMID 30274985, PMID 34343033, PMID 35640224, PMID 35790816, PMID 32299817, PMID 32615108, PMID 33301227, PMID 33465704, PMID 33740926, PMID 34663404, PMID 34873345, PMID 34873347, PMID 36477870, PMID 37105265, PMID 38320129, PMID 41244098, PMID 41604606, PMID 41690487
2015 (1), 2017 (1), 2018 (1), 2019 (1), 2023 (1)